Dutch 
English 
French Batch processing in pharmaceutical manufacturingÂ
Explore batch processing in pharmaceutical manufacturing, including GMP traceability, quality control, flexible production and batch release.
Fundamental approach to pharmaceutical manufacturing
Batch processing remains a fundamental approach to pharmaceutical manufacturing, supporting GMP compliance, product traceability, flexible production and controlled quality assurance.
Batch processing remains a fundamental approach to pharmaceutical manufacturing, supporting GMP compliance, product traceability, flexible production and controlled quality assurance.
Batch processing is not simply a legacy convention in pharmaceutical manufacturing; it is a deliberate, regulatory-aligned production philosophy that continues to define how active pharmaceutical ingredients (APIs) and finished dosage forms are made. Understanding why requires looking at the intersection of regulatory obligation, operational complexity, and scientific precision that characterizes modern drug production.
From pharmaceutical research and development to commercial API manufacturing, batch processes provide clearly defined production stages, documented operating conditions and structured quality control procedures.
This makes batch processing particularly relevant for multi-step synthesis, purification, crystallization and other pharmaceutical operations where process flexibility and traceability are essential.
What is batch processing in pharmaceutical manufacturing?
Batch processing is a manufacturing approach in which a defined quantity of material is processed through a specified sequence of operations. Each production batch follows established procedures and is associated with documentation covering its manufacturing history, process parameters and quality results.
In pharmaceutical manufacturing, batch processing can involve several interconnected unit operations, including chemical synthesis, reaction control, separation, crystallization, filtration, drying and formulation.
Unlike continuous manufacturing, where material moves through an interconnected process over time, batch manufacturing typically involves processing discrete quantities of material through individual production stages.
This approach provides several important advantages for pharmaceutical manufacturers:
GMP traceability: each batch is associated with defined manufacturing records and quality documentation.
Production flexibility: equipment can be used for different products, processes and production scales.
Quality control: individual batches can be evaluated against established specifications before release.
Process control: critical manufacturing parameters can be monitored and documented throughout production.
Controlled changeovers: defined production boundaries facilitate equipment cleaning, verification and product changeover.
These characteristics help explain why batch processing continues to play an important role in pharmaceutical research, API production and commercial manufacturing.
GMP traceability and lot-based purification
At the core of pharmaceutical batch processing is the concept of the defined lot, a quantity of material produced under a single set of conditions and assigned a unique batch or lot number. This is not administrative housekeeping; it is the foundation of Good Manufacturing Practice (GMP) as codified in EU GMP Annex 15, ICH Q7 (for APIs), and 21 CFR Parts 210–211 in the US.
Each batch carries a complete, auditable history: raw material provenance and Certificate of Analysis (CoA), in-process controls at each production stage, environmental monitoring data, equipment usage and cleaning logs, and release testing results tied to that specific lot. This lot-level traceability is indispensable for deviation investigations, product recall execution, and regulatory inspections.Â
When an out-of-specification (OOS) result is triggered, the batch record localizes the investigation to a bounded production event rather than an indeterminate continuous output, reducing scope, accelerating root cause analysis, and containing the impact.
From a regulatory standpoint, this traceability architecture is essentially mandatory. FDA and EMA expectations for batch records, batch genealogy, and lot retention samples are built around discrete production units. Continuous manufacturing is gaining traction, but even those processes require defined “process analytical technology (PAT)-based” batch definitions to meet current regulatory frameworks.
The role of batch records in pharmaceutical manufacturing
Batch records provide documented evidence of how a pharmaceutical product or intermediate was manufactured. They connect production activities, equipment, materials, operating conditions and quality control results to a specific manufacturing lot.
For pharmaceutical manufacturers, this documentation supports several essential activities:
Demonstrating compliance with approved manufacturing procedures.
Reviewing critical process parameters and in-process controls.
Investigating deviations and out-of-specification results.
Establishing traceability between raw materials, intermediates and finished products.
Supporting quality assurance reviews and batch disposition decisions.
The ability to reconstruct a batch’s manufacturing history is particularly important in regulated environments where process consistency, documentation and product quality must be demonstrated.
Flexibility for multi-product facilities
Campaign-based batch manufacturing enables pharmaceutical facilities to produce multiple distinct products on shared infrastructure, a critical economic and operational requirement for contract development and manufacturing organizations (CDMOs) and multi-product API plants alike.
In a batch environment, the production of Product A is fully completed, equipment is cleaned and verified (cleaning validation per ICH Q7 section 12), and the facility is then qualified to run Product B.Â
This sequential, campaign-based structure provides a controlled mechanism for product changeover that is difficult to replicate in continuous systems without extensive dedicated lines.
Flexible scaling and controlled changeover
The batch paradigm also supports scale flexibility. A facility can run a development batch of 5 kg, a clinical supply batch of 50 kg, and a commercial batch of 500 kg using the same underlying process, adjusting equipment size while maintaining the batch control logic.Â
This is particularly relevant during the transition from Phase II to Phase III clinical trials, where supply requirements can increase by one to two orders of magnitude within a 12–18 month window.
For facilities operating under shared equipment policies, the batch structure provides clearly defined start and end points for equipment occupancy, cleaning procedures, and line clearance, all of which are auditable under GMP. Contamination risk between products, including cross-contamination from potent compounds or allergens, is managed at the batch boundary.
Quality control and batch release in pharmaceutical manufacturing
Quality control in pharmaceutical manufacturing operates on the fundamental principle of batch release: a defined quantity of product is tested comprehensively, evaluated against its specifications, and either released to market or rejected as a discrete unit. This decision logic maps directly onto batch production.
The battery of release tests applied to a typical API batch, identity (IR, NMR), purity (HPLC), related substances, residual solvents (GC headspace), water content (Karl Fischer), heavy metals, microbiological limits, and physical characterisation, generates a complete quality profile for that specific production unit. Statistical sampling plans (e.g., per ISO 2859) are applied to the batch as a population, with scientifically justified sampling frequencies that assume lot homogeneity.
Batch record reviewÂ
Batch records serve as the primary vehicle for quality review. The batch record review (BRR) process, carried out by quality assurance prior to release, examines the entire production and testing history in one consolidated document set.Â
This concentrated, batch-specific review is a practical and regulatory expectation under CFR 211.192 and EU GMP Chapter 4.
When a batch fails specification, the quarantine, investigation, and disposition process operates cleanly: the batch is isolated, the investigation is scoped to that lot’s production window, and the impact assessment for other lots uses the batch traceability record to determine whether related lots were affected.Â
This containment logic is one of the defining quality advantages of lot-based manufacturing over continuous production, where failure modes can, if not carefully managed, be distributed across a broader and less precisely bounded output.
Common batch processing operations in pharmaceutical manufacturing
Pharmaceutical batch manufacturing involves different unit operations depending on the product, manufacturing stage and process requirements.
For active pharmaceutical ingredient production, these operations may include chemical reactions, intermediate purification, crystallization, solid-liquid separation and drying. Each operation has its own process requirements and can influence the quality and consistency of the final material.
Chemical synthesis and reaction control
Batch reactors are widely used in pharmaceutical chemical synthesis, particularly where multi-step reactions require defined reaction times, controlled reagent addition and precise temperature management.
Reaction conditions can be adjusted and monitored throughout the process to support the desired chemical transformation.
Crystallization and purification
Crystallization is an important operation in many pharmaceutical API manufacturing processes. Controlled crystallization conditions can influence properties such as crystal formation, particle characteristics and the separation of the desired compound from the surrounding liquid phase.
Batch processing allows manufacturers to establish and monitor conditions for individual crystallization operations.
Filtration, washing and drying
Following crystallization or precipitation, solid materials often require separation from the liquid phase. Filtration, washing and drying operations can be performed as individual batch steps or combined within suitable equipment configurations.
The selection of equipment and operating conditions depends on the properties of the material and the requirements of the manufacturing process.
Our solutions
Comparative dissolution tester
CD14Â
Enables simultaneous or independent dissolution testing with 14 stirring positions and flexible method settings. Supports bioequivalence studies, automated sampling and secure data management.
Automated dissolution sampling
Vision AutoPlus with AutoFill
Automates dissolution sampling and sample collection with 6 or 8 channels. Features precision syringe pumps, flexible collection formats and integration with UV-Vis, HPLC and UPLC workflows.
Dissolutietest
Vision G2 Classic 6
Enables precise dissolution testing with 6 vessel positions, programmable speed and temperature control. Features a compact design, intuitive touchscreen and optional automated sampling.
Dissolutietest
Vision G2 Elite 8
Enables precise dissolution testing with 8 vessel positions and flexible manual or automated operation. Features adjustable drive head, touchscreen control and advanced sampling options.
Microwave digestion system
BLADE
An automated sequential microwave digestion system. It processes vessels individually and allows different samples and acid mixtures to be combined within one sequence
Scientific digestion system
MARSXpress 2.0
A batch microwave system that can process between one and 41 samples. It flexible vessel range makes it suitable for routine digestion across varied sample types.Â
Discuss your application with our Xperts
Our Xperts are happy to discuss your application and help you find the right solution.
FAQ
Why does the pharmaceutical industry still use batch processing?
Pharmaceutical manufacturers rely on batch processing because it supports GMP compliance, lot traceability, product quality control, and regulatory oversight. Each batch is produced under a defined set of conditions and can be fully traced from raw materials to finished product.
What is batch processing in pharmaceutical manufacturing?
Batch processing is a manufacturing approach where a defined quantity of material is produced as a single lot under controlled conditions. Each batch receives a unique identifier and is documented independently for quality, regulatory, and traceability purposes.
Why is batch processing important for GMP compliance?
Batch processing creates clear production boundaries, making it possible to document raw materials, processing conditions, equipment usage, cleaning records, environmental monitoring data, and testing results for each individual lot.
How does batch processing help with deviation investigations?
When an unexpected event occurs, investigators can focus on a specific production lot rather than reviewing continuous production data across extended manufacturing periods.
What information is included in a pharmaceutical batch record?
A batch record typically includes raw material information, Certificates of Analysis, process parameters, cleaning records, equipment logs, environmental monitoring data, in-process testing results, and final release test results.
How does batch manufacturing support pharmaceutical quality assurance?
Quality assurance teams can review all production and testing data associated with a specific batch before deciding whether it meets release requirements.
Which tests are commonly performed on API batches?
Common API release tests include identity testing, HPLC purity analysis, related substances testing, residual solvent analysis, water content measurement, heavy metal testing, and microbiological assessment where applicable.
How does batch processing simplify quality investigations?
If a quality issue arises, manufacturers can isolate the affected batch, investigate a specific production window, and determine whether related batches may have been impacted.
What are the advantages of batch manufacturing compared with continuous manufacturing?
Batch manufacturing offers strong traceability, well-established regulatory acceptance, straightforward quality review, clear product segregation, and flexibility for multi-product facilities.